da Silva IP, Ahmed T, Reijers ILM, et al. - Researchers undertook this multicentre, retrospective, cohort study to investigate the efficacy as well as safety of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) vs ipilimumab monotherapy in metastatic melanoma patients who are resistant to anti-PD-(L)1 therapy. Participants were adult patients (aged ≥18 years) suffering from metastatic melanoma (unresectable stage III and IV), exhibiting resistance to anti-PD-(L)1 (innate or acquired resistance) and they were treated with either ipilimumab monotherapy or ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab), on the basis of availability of therapies or clinical factors ascertained by the physician, or both. A higher objective response rate, longer progression-free, and longer overall survival as well as similar rate of grade 3–5 toxicity were conferred by ipilimumab plus anti-PD-1 when compared with ipilimumab, and thus, a higher efficacy seemed to be offered by ipilimumab plus anti-PD-1 vs ipilimumab in patients who were resistant to anti-PD-(L)1 in this study. In the light of these data, preference should be given to ipilimumab plus anti-PD-1 over ipilimumab alone as a second-line immunotherapy for these patients suffering from advanced melanoma.